GlobeNewswire: Asterias Biotherapeutics Contains the last 10 of 48 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:56:54ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/01/24/1704757/0/en/Asterias-Provides-Top-Line-12-Month-Data-Update-for-its-OPC1-Phase-1-2a-Clinical-Trial-in-Severe-Spinal-Cord-Injury.html?f=22&fvtc=4&fvtv=36395Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury2019-01-24T12:00:00Z<![CDATA[FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided top-line 12 month data from the Company’s Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord injury (SCI). All 25 subjects from the SCiStar study have now completed 12-months of follow-up as part of the study’s protocol. The Company also held a Type B meeting with the Food and Drug Administration (FDA) late last year where FDA agreed with the Company’s plan to initiate a randomized, controlled Phase 2 study to further evaluate the safety and efficacy of OPC1.]]>https://www.globenewswire.com/news-release/2018/11/27/1657296/0/en/Asterias-Biotherapeutics-Announces-Fourth-Patient-Dosed-in-First-in-Human-Clinical-Study-of-Immunotherapy-VAC2-in-Non-Small-Cell-Lung-Cancer.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer2018-11-27T12:00:00Z<![CDATA[Two Sites in the UK Currently Enrolling Patients Two Sites in the UK Currently Enrolling Patients]]>https://www.globenewswire.com/news-release/2018/11/09/1649206/0/en/Asterias-Biotherapeutics-Reports-Third-Quarter-Results.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics Reports Third Quarter Results2018-11-09T21:10:00Z<![CDATA[Clinical Programs Continue to ProgressRecent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating ExpensesRecently Announced Definitive Merger Agreement with BioTime Creates Leading Cell Therapy Company]]>https://www.globenewswire.com/news-release/2018/11/02/1641924/0/en/Asterias-Biotherapeutics-to-Report-Third-Quarter-2018-Results-on-November-12-2018.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 20182018-11-02T11:00:00Z<![CDATA[FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release third quarter 2018 financial and operating results on Monday, November 12, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on November 12, 2018 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and corporate developments.]]>https://www.globenewswire.com/news-release/2018/10/31/1640333/0/en/Asterias-Biotherapeutics-Announces-Positive-Outcome-from-Data-Review-from-OPC1-Spinal-Cord-Injury-Study.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study2018-10-31T13:45:00Z<![CDATA[Meeting with Food and Drug Administration Remains on Track for End of 2018]]>https://www.globenewswire.com/news-release/2018/10/01/1587596/0/en/Asterias-Biotherapeutics-Announces-Facilities-and-IP-License-Option-Agreements.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics Announces Facilities and IP License Option Agreements2018-10-01T11:00:00Z<![CDATA[Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed Overhead Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed Overhead]]>https://www.globenewswire.com/news-release/2018/09/20/1573565/0/en/FDA-Accepts-Asterias-Biotherapeutics-Request-to-Meet-and-Discuss-Next-Phase-of-Development-for-OPC1-Spinal-Cord-Injury-Clinical-Program.html?f=22&fvtc=4&fvtv=36395FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program2018-09-20T11:00:00Z<![CDATA[FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the Food and Drug Administration (FDA) has accepted its request to meet to discuss proposed next steps for the OPC1 clinical development program. The Company’s Type B meeting request was made in accordance with the Regenerative Medicine Advanced Therapy (RMAT) designation under the 21st Century Cures Act.]]>https://www.globenewswire.com/news-release/2018/09/12/1569609/0/en/Asterias-Provides-24-Month-Cohort-2-Update-for-its-OPC1-Phase-1-2a-Clinical-Trial-in-Severe-Spinal-Cord-Injury.html?f=22&fvtc=4&fvtv=36395Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury2018-09-12T11:00:00Z<![CDATA[FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the Company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord injury. All 6 subjects from Cohort 2 in the SCiStar study have now completed a 24-month follow-up as part of the study’s long-term follow-up protocol and each subject either retained the motor function recovery seen through 12 months or saw further motor function recovery from 12 to 24 months.]]>https://www.globenewswire.com/news-release/2018/09/04/1564744/0/en/Asterias-Biotherapeutics-Announces-Positive-Outcome-from-Second-Safety-Review-Committee-Meeting-and-Open-Enrollment-for-VAC2-Clinical-Trial-in-Non-Small-Cell-Lung-Cancer-NSCLC.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)2018-09-04T11:00:00Z<![CDATA[Two Sites in the UK Currently Enrolling Patients Two Sites in the UK Currently Enrolling Patients]]>https://www.globenewswire.com/news-release/2018/08/29/1558142/0/en/Asterias-Biotherapeutics-CEO-Michael-Mulroy-to-Participate-on-Regenerative-Medicine-Therapies-Panel-at-the-B-Riley-FBR-Healthcare-Conference.html?f=22&fvtc=4&fvtv=36395Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference2018-08-29T11:00:00Z<![CDATA[FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Michael Mulroy, President and Chief Executive Officer, will participate in a panel discussion at the B. Riley FBR Healthcare Conference at 8:20am ET/5:20 am PT on Tuesday, September 4, 2018 in New York.]]>